ES2442242B1 - Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación. - Google Patents

Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación. Download PDF

Info

Publication number
ES2442242B1
ES2442242B1 ES201200810A ES201200810A ES2442242B1 ES 2442242 B1 ES2442242 B1 ES 2442242B1 ES 201200810 A ES201200810 A ES 201200810A ES 201200810 A ES201200810 A ES 201200810A ES 2442242 B1 ES2442242 B1 ES 2442242B1
Authority
ES
Spain
Prior art keywords
composition
nervous system
growth factors
central nervous
pathology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201200810A
Other languages
English (en)
Spanish (es)
Other versions
ES2442242A1 (es
Inventor
Eduardo Anitua Aldecoa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTI Biotechnology Insttitute
Original Assignee
BTI Biotechnology Insttitute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49111229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2442242(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BTI Biotechnology Insttitute filed Critical BTI Biotechnology Insttitute
Priority to ES201200810A priority Critical patent/ES2442242B1/es
Priority to TW102125858A priority patent/TWI649084B/zh
Priority to RU2015104076A priority patent/RU2696497C2/ru
Priority to PE2015000116A priority patent/PE20150616A1/es
Priority to MX2015001677A priority patent/MX357828B/es
Priority to PCT/ES2013/000176 priority patent/WO2014023860A1/es
Priority to EP13756518.0A priority patent/EP2883569B1/en
Priority to CA2881075A priority patent/CA2881075A1/en
Priority to JP2015525915A priority patent/JP6339568B2/ja
Priority to KR1020157001551A priority patent/KR102149162B1/ko
Priority to CN201380041280.4A priority patent/CN104519961A/zh
Priority to ES13756518.0T priority patent/ES2662385T3/es
Priority to BR112015002760A priority patent/BR112015002760A2/pt
Priority to ARP130102835A priority patent/AR092086A1/es
Priority to US13/962,340 priority patent/US20140044795A1/en
Publication of ES2442242A1 publication Critical patent/ES2442242A1/es
Publication of ES2442242B1 publication Critical patent/ES2442242B1/es
Application granted granted Critical
Priority to CL2014003510A priority patent/CL2014003510A1/es
Priority to IN2675MUN2014 priority patent/IN2014MN02675A/en
Priority to CO15010369A priority patent/CO7170177A2/es
Priority to US15/063,969 priority patent/US20160184360A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ES201200810A 2012-08-09 2012-08-09 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación. Expired - Fee Related ES2442242B1 (es)

Priority Applications (19)

Application Number Priority Date Filing Date Title
ES201200810A ES2442242B1 (es) 2012-08-09 2012-08-09 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
CN201380041280.4A CN104519961A (zh) 2012-08-09 2013-07-19 用于神经退行性疾病或中枢神经系统的其他疾病的鼻内治疗的含有生长因子的组合物,及其制造方法
BR112015002760A BR112015002760A2 (pt) 2012-08-09 2013-07-19 composição com fatores de crescimento, para ser usada no tratamento intranasal de uma doença neurodegenerativa ou outras doenças do sistema nervoso central, e seu método de fabricação
PE2015000116A PE20150616A1 (es) 2012-08-09 2013-07-19 Composicion que comprende factores de crecimiento obtenidos a partir del plasma sanguineo
MX2015001677A MX357828B (es) 2012-08-09 2013-07-19 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
PCT/ES2013/000176 WO2014023860A1 (es) 2012-08-09 2013-07-19 Composición con factores de crecimiento obtenidos a partir del plasma sanguíneo destinada al tratamiento de enfermedades neurodegenerativas
EP13756518.0A EP2883569B1 (en) 2012-08-09 2013-07-19 Compositions comprising plasma growth factors for use in the treatment of neurodegenerative disorders
CA2881075A CA2881075A1 (en) 2012-08-09 2013-07-19 Composition with growth factors, to be used in the intranasal treatment of a neurodegenerative disease or other diseases of the central nervous system, and its method of manufacture
JP2015525915A JP6339568B2 (ja) 2012-08-09 2013-07-19 神経変性障害の治療で使用するための血漿中の成長因子を含む組成物
KR1020157001551A KR102149162B1 (ko) 2012-08-09 2013-07-19 신경퇴행성 질환의 치료에 사용하기 위한 혈장 성장 인자를 포함하는 조성물
TW102125858A TWI649084B (zh) 2012-08-09 2013-07-19 用於阿茲海默症之鼻內治療的具有生長因子之組成物之用途
ES13756518.0T ES2662385T3 (es) 2012-08-09 2013-07-19 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa
RU2015104076A RU2696497C2 (ru) 2012-08-09 2013-07-19 Композиция с факторами роста для применения в интраназальном лечении нейродегенеративного заболевания или других заболеваний центральной нервной системы и способ ее получения
ARP130102835A AR092086A1 (es) 2012-08-09 2013-08-08 Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion
US13/962,340 US20140044795A1 (en) 2012-08-09 2013-08-08 Composition with growth factors, to be used in the intranasal treatment of a neurodegenerative disease or other diseases of the central nervous system, and its method of manufacture
CL2014003510A CL2014003510A1 (es) 2012-08-09 2014-12-23 Composición con factores de crecimiento obtenidos a partir del plasma sanguíneo destinada al tratamiento de enfermedades neurodegenerativas.
IN2675MUN2014 IN2014MN02675A (https=) 2012-08-09 2014-12-31
CO15010369A CO7170177A2 (es) 2012-08-09 2015-01-20 Composición de factores de crecimiento obtenidos a partir del plasma sanguíneo destinada al tratamiento de enfermedades neurodegenerativas
US15/063,969 US20160184360A1 (en) 2012-08-09 2016-03-08 Composition with growth factors, to be used in the intranasal treatment of a neurodegenerative disease or other diseases of the central nervous system, and its method of manufacture

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201200810A ES2442242B1 (es) 2012-08-09 2012-08-09 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.

Publications (2)

Publication Number Publication Date
ES2442242A1 ES2442242A1 (es) 2014-02-10
ES2442242B1 true ES2442242B1 (es) 2014-11-25

Family

ID=49111229

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201200810A Expired - Fee Related ES2442242B1 (es) 2012-08-09 2012-08-09 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
ES13756518.0T Active ES2662385T3 (es) 2012-08-09 2013-07-19 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13756518.0T Active ES2662385T3 (es) 2012-08-09 2013-07-19 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa

Country Status (17)

Country Link
US (2) US20140044795A1 (https=)
EP (1) EP2883569B1 (https=)
JP (1) JP6339568B2 (https=)
KR (1) KR102149162B1 (https=)
CN (1) CN104519961A (https=)
AR (1) AR092086A1 (https=)
BR (1) BR112015002760A2 (https=)
CA (1) CA2881075A1 (https=)
CL (1) CL2014003510A1 (https=)
CO (1) CO7170177A2 (https=)
ES (2) ES2442242B1 (https=)
IN (1) IN2014MN02675A (https=)
MX (1) MX357828B (https=)
PE (1) PE20150616A1 (https=)
RU (1) RU2696497C2 (https=)
TW (1) TWI649084B (https=)
WO (1) WO2014023860A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2016003282A1 (es) 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2252993T3 (es) * 1998-12-09 2006-05-16 Chiron Corporation Administracion de agentes neurotroficos al sistema nervioso central.
AR022333A1 (es) * 1999-01-26 2002-09-04 Anitua Aldecoa Eduardo Regenerador de tejido oseo
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
ES2221770B2 (es) 2002-04-19 2006-07-16 Eduardo Anitua Aldecoa Metodo de preparacion de un compuesto para la regeneracion de tejidos.
US20060004189A1 (en) * 2004-07-02 2006-01-05 James Gandy Compositions for treating wounds and processes for their preparation
CA2620202C (en) * 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
EP2152240A4 (en) * 2007-06-08 2012-05-09 Healthpartners Res Foundation PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM
ES2333498B1 (es) * 2007-08-02 2011-01-10 Biotechnology Institute, I Mas D, S.L. Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros, y el metodo de preparacion del compuesto.
EP2212344B1 (en) * 2007-09-14 2014-03-26 Formycon AG Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
MX2011011921A (es) 2009-05-14 2011-12-06 Biotechnology Inst I Mas D Sl Metodo para la preparacion de al menos un compuesto a partir de sangre, y dispositivo de extraccion para ser utilizado en la ejecucion de dicho metodo.
KR101114712B1 (ko) * 2009-10-23 2012-02-29 세원셀론텍(주) 염화칼슘용액과 제1형 콜라겐으로 혈소판풍부혈장(ｐｒｐ)을 활성화하여 조직재생을 유도하는 조성물의 제조방법
ES2369945B1 (es) 2011-07-29 2012-10-15 Eduardo Anitua Aldecoa Procedimiento de obtención de una composición que contiene factores de crecimiento a partir de un compuesto sanguíneo, y composición obtenible por dicho procedimiento.

Also Published As

Publication number Publication date
WO2014023860A1 (es) 2014-02-13
MX2015001677A (es) 2015-04-10
EP2883569A1 (en) 2015-06-17
CL2014003510A1 (es) 2015-05-04
IN2014MN02675A (https=) 2015-08-28
TWI649084B (zh) 2019-02-01
BR112015002760A2 (pt) 2020-04-22
EP2883569B1 (en) 2017-12-20
ES2442242A1 (es) 2014-02-10
ES2662385T3 (es) 2018-04-06
KR102149162B1 (ko) 2020-08-31
JP2015524464A (ja) 2015-08-24
MX357828B (es) 2018-07-25
TW201408310A (zh) 2014-03-01
AR092086A1 (es) 2015-03-25
RU2015104076A (ru) 2016-09-27
US20140044795A1 (en) 2014-02-13
PE20150616A1 (es) 2015-05-25
JP6339568B2 (ja) 2018-06-06
CA2881075A1 (en) 2014-02-13
CN104519961A (zh) 2015-04-15
CO7170177A2 (es) 2015-01-28
KR20150040860A (ko) 2015-04-15
RU2696497C2 (ru) 2019-08-02
US20160184360A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
IL243481A0 (en) Drug for treatment of nonalcoholic fatty liver disease
CL2015001442A1 (es) Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico.
BR112015001098A2 (pt) composto, composição farmacêutica e método para o tratamento de uma condição de doença.
ES2641862T3 (es) Proceso para la elaboración de inhibidores de CCR3
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
ES2421956B1 (es) Nueva forma cristalina de sulfato de sitagliptina
BR112014026149A2 (pt) método para a preparação de 2,4-ácido dihidroxibutírico (2,4-dhb) e microrganismo.
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
EP2959903A4 (en) MEDICAMENT FOR THE TREATMENT OF EYE DRESSING
IL220318A (en) Aqueous solutions comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart diseases
CA3290933A1 (en) Oral octreotide for the treatment of disease
IL255506A (en) A method for treating a neurological disease
IL259297A (en) Heterocyclic compounds for the treatment of disease
ES2811674R1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
LT3251675T (lt) Šlapimo rūgšties (kaupimosi) arba podagros ligos prevencija arba gydymas
ITUA20162696A1 (it) Procedimento per il funzionamento di un sistema composito formato da almeno un filatoio ad anelli e da almeno un incannatoio, nonche' sistema composito
ES2442242B1 (es) Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
ES2486441B1 (es) Preparaciones combinadas de acidificantes urinarios e inhibidores de la cristalización y su aplicación para el tratamiento o prevención de la litiasis renal fosfática o inducida por fosfato cálcico
LT3322438T (lt) Il-8 inhibitoriai, skirti naudoti tam tikrų urologinių susirgimų gydymui
ES2537905B2 (es) Uso de 12- desoxiforboles para promover la proliferación de las células madre neurales
ES2525079A1 (es) Actividad antiparasitaria de escuaramidas
ES2547027B1 (es) Procedimiento para la preparación de derivados de 1,1,2-trialquil-1H-indeno a partir de derivados de 2-(1,1,2-trialquil-3-oxopropil)benzaldehído
ES2473320B1 (es) Uso del factor de crecimiento derivado de plaquetas para el tratamiento de las calcificaciones vasculares
FR3006324B1 (fr) Procede de preparation d'un polyamide ester de gelatine.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2442242

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20141125

FD2A Announcement of lapse in spain

Effective date: 20210928